Technical Analysis for PRLD - Prelude Therapeutics Incorporated

Grade Last Price % Change Price Change
F 32.7 -7.26% -2.56
PRLD closed down 7.26 percent on Monday, April 12, 2021, on 2.09 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical PRLD trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -7.26%
Oversold Stochastic Weakness -7.26%
Multiple of Ten Bearish Other -12.54%
Wide Bands Range Expansion -12.54%
Oversold Stochastic Weakness -12.54%
Narrow Range Bar Range Contraction -16.69%
Multiple of Ten Bearish Other -16.69%
Older End-of-Day Signals for PRLD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 6 hours ago
Down 5% about 7 hours ago
2x Volume Pace about 7 hours ago
1.5x Volume Pace about 7 hours ago
Down 3% about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Prelude Therapeutics Incorporated Description

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Solid Tumors Cancers Lymphoma Wilmington Blastoma Glioblastoma Tyrosine Kinase Receptors Small Molecule Therapies Protein Kinase Inhibitors Phosphoinositide 3 Kinase Inhibitor Glioblastoma Multiforme

Is PRLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 95.375
52 Week Low 24.0
Average Volume 176,841
200-Day Moving Average 0.00
50-Day Moving Average 61.09
20-Day Moving Average 45.89
10-Day Moving Average 38.88
Average True Range 4.50
ADX 29.17
+DI 13.25
-DI 33.69
Chandelier Exit (Long, 3 ATRs ) 49.26
Chandelier Exit (Short, 3 ATRs ) 46.00
Upper Bollinger Band 62.14
Lower Bollinger Band 29.64
Percent B (%b) 0.09
BandWidth 70.82
MACD Line -7.09
MACD Signal Line -6.59
MACD Histogram -0.493
Fundamentals Value
Market Cap 1.43 Billion
Num Shares 43.7 Million
Price-to-Sales 0.00
Price-to-Book 9.76
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.01
Resistance 3 (R3) 38.53 37.29 37.12
Resistance 2 (R2) 37.29 35.94 37.03 36.83
Resistance 1 (R1) 35.00 35.10 34.37 34.47 36.53
Pivot Point 33.75 33.75 33.44 33.49 33.75
Support 1 (S1) 31.46 32.40 30.84 30.93 28.87
Support 2 (S2) 30.22 31.57 29.95 28.57
Support 3 (S3) 27.92 30.22 28.28
Support 4 (S4) 27.39